Dmitry Balyasny’s Royalty Pharma RPRX Stock Holding History

Dmitry Balyasny’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-27,511	Closed	-$971K	–	3488
2025 Q3	$971K	Buy	+27,511	New	+$996K	﹤0.01%	2124
2025 Q1	–	Sell	-59,755	Closed	-$1.52M	–	3218
2024 Q4	$1.52M	Buy	+59,755	New	+$1.58M	﹤0.01%	1770
2024 Q1	–	Sell	-95,382	Closed	-$2.68M	–	3050
2023 Q4	$2.68M	Buy	95,382 +27,445	+40%	+$754K	0.01%	1357
2023 Q3	$1.84M	Buy	+67,937	New	+$2.02M	﹤0.01%	1395
2022 Q4	–	Sell	-285,034	Closed	-$11.5M	–	3173
2022 Q3	$11.5M	Buy	+285,034	New	+$12.2M	0.04%	625
2022 Q2	–	Sell	-197,889	Closed	-$7.71M	–	3112
2022 Q1	$7.71M	Buy	+197,889	New	+$7.77M	0.02%	788

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dmitry Balyasny's RPRX Position: Q4 2025 in Review

Dmitry Balyasny sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 27,511 shares — an estimated $971K sold.

Dmitry Balyasny first reported a position in RPRX in Q1 2022 and held it in 6 quarters. The position peaked at $11.5M in Q3 2022. 539 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

Dmitry Balyasny reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
Dmitry Balyasny sold 27,511 Royalty Pharma shares in Q4 2025, an estimated $971K.
Dmitry Balyasny first reported a position in Royalty Pharma in Q1 2022 and held it in 6 quarters.
Dmitry Balyasny's Royalty Pharma position peaked at $11.5M in Q3 2022.
539 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.